FDA Relies On Cognition Research To Spot Misleading Ads – Draft Guidance

FDA is harnessing established science on human cognition to assess whether a device or drug maker's advertisement is misleading, according to a May 27 draft 1guidance document from the agency

More from Archive

More from Medtech Insight